Zydus Cadila has received the final approval from the USFDA to market Desvenlafaxine Extended-Release Tablets, 50 mg and 100 mg. The drug is used to treat major depression and will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.
The group now has more than 160 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.492 as compared to the previous close of Rs. 492.15. The total number of shares traded during the day was 13321 in over 309 trades.
The stock hit an intraday high of Rs. 495.5 and intraday low of 487. The net turnover during the day was Rs. 6544687.